Foreign investors are stepping up acquisitions of Japanese drug makers. Under the Foreign Exchange and Foreign Trade Act (FEFTA), such…
BUSINESS
Takeda to Split Part of Research Biz Into New Subsidiary
Takeda Pharmaceutical said on May 15 that it has formed a wholly owned subsidiary that would take over part of the company’s research operations in Japan as part of its global R&D transformation to boost its focus on priority therapeutic…
To read the full story
Related Article
- Spera Pharma Begins Business Capitalizing on “Takeda’s” Track Record, Aims to Become Japan’s No. 1 CDMO
September 6, 2017
- External Activities of Takeda Unit Axcelead to Go Full Throttle This Autumn: President
August 23, 2017
- Takeda’s Drug Discovery Support Subsidiary Now Up and Running
July 11, 2017
- Takeda to Transfer Part of CMC Functions to Bushu
March 1, 2017
BUSINESS
- Kisunla Uptake “as Expected” One Year after Approval, Says Lilly Japan Exec
September 19, 2025
- SanBio Eyes Akuugo Label Expansion Talks with PMDA in FY2026
September 19, 2025
- Deciphera’s Romvimza Scores EU Nod as First TGCT Therapy
September 19, 2025
- Lilly Japan Adds Tablet Formulation for Retevmo
September 19, 2025
- Nihon Chouzai Tender Offer Completed, Set to Delist under Advantage Partners
September 18, 2025
MSD’s new pulmonary arterial hypertension (PAH) therapy Airwin (sotatercept) hit the Japanese market in mid-August. It’s the kind of launch…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…